Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...